ATE438405T1 - Verwendung von peptidantagonisten des zonulin zur behandlung von diabetes - Google Patents

Verwendung von peptidantagonisten des zonulin zur behandlung von diabetes

Info

Publication number
ATE438405T1
ATE438405T1 AT01922244T AT01922244T ATE438405T1 AT E438405 T1 ATE438405 T1 AT E438405T1 AT 01922244 T AT01922244 T AT 01922244T AT 01922244 T AT01922244 T AT 01922244T AT E438405 T1 ATE438405 T1 AT E438405T1
Authority
AT
Austria
Prior art keywords
diabetes
treatment
peptide antagonists
zonulin peptide
zonulin
Prior art date
Application number
AT01922244T
Other languages
German (de)
English (en)
Inventor
Alessio Fasano
Tammara Watts
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Application granted granted Critical
Publication of ATE438405T1 publication Critical patent/ATE438405T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/843—Digestive system
    • Y10S530/844—Stomach; intestine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AT01922244T 2000-05-19 2001-03-21 Verwendung von peptidantagonisten des zonulin zur behandlung von diabetes ATE438405T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20530500P 2000-05-19 2000-05-19
PCT/US2001/005825 WO2001089551A1 (en) 2000-05-19 2001-03-21 Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes

Publications (1)

Publication Number Publication Date
ATE438405T1 true ATE438405T1 (de) 2009-08-15

Family

ID=22761653

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01922244T ATE438405T1 (de) 2000-05-19 2001-03-21 Verwendung von peptidantagonisten des zonulin zur behandlung von diabetes

Country Status (8)

Country Link
US (6) US7026294B2 (enExample)
EP (1) EP1282432B1 (enExample)
JP (3) JP2003534287A (enExample)
AT (1) ATE438405T1 (enExample)
AU (1) AU2001249067A1 (enExample)
CA (1) CA2409771C (enExample)
DE (1) DE60139466D1 (enExample)
WO (1) WO2001089551A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458925B1 (en) * 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
WO2001089551A1 (en) * 2000-05-19 2001-11-29 University Of Maryland, Baltimore Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
AU2004259705B2 (en) * 2003-07-15 2009-04-23 University Of Maryland, Baltimore Agonist polypeptide of receptor for zot and zonulin
US20090176244A1 (en) * 2005-05-13 2009-07-09 Bai Julio Methods and compositions for the diagnosis of crohn's disease
TW200716159A (en) * 2005-06-09 2007-05-01 Univ Maryland Method of use of antagonists of zonulin to prevent the loss of or to regenerate pancreatic cells
CN101420850A (zh) * 2006-02-09 2009-04-29 阿尔巴医疗公司 紧密连接效应子的制剂
AU2012203787B2 (en) * 2006-02-09 2014-07-10 Alba Therapeutics Corporation Formulations for a Tight Junction Effector
WO2008043107A2 (en) * 2006-10-06 2008-04-10 Alba Therapeutics Corporation Use of tight junction antagonists to treat inflammatory bowel disease
WO2008052185A2 (en) * 2006-10-26 2008-05-02 Alba Therapeutics Corp Materials and methods for the treatment of celiac disease
EP2091551B1 (en) * 2006-11-03 2020-01-15 Alba Therapeutics Corporation Method of treating asthma
AT504214B1 (de) * 2007-01-03 2008-04-15 Bernhard Hans Peter Dipl Ing D Verfahren zur dynamischen, datenabhängigen bestimmung und anwendung von berechtigungen in hierarchischen und relationalen umgebungen
US8728491B2 (en) * 2007-05-07 2014-05-20 Alba Therapeutics Corporation Transcutaneous delivery of therapeutic agents
US20110201543A1 (en) * 2007-06-29 2011-08-18 Blake Paterson Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress
US8198233B2 (en) 2007-07-26 2012-06-12 Alba Therapeutics Corporation Synthetic peptides that enhance tight junction permeability
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
EP2062909A1 (en) 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
WO2009137436A2 (en) * 2008-05-05 2009-11-12 Alba Therapeutics Corporation Peptide conjugates
US8957032B2 (en) 2008-05-06 2015-02-17 Alba Therapeutics Corporation Inhibition of gliadin peptides
US20190358288A1 (en) 2017-02-10 2019-11-28 Innovate Biopharmaceuticals, Inc. Compositions and methods for treating or preventing environmental enteropathy
KR20180107341A (ko) * 2017-03-16 2018-10-02 차의과학대학교 산학협력단 칼륨 경쟁적 위산분비억제제를 유효성분을 함유하는 장 누수 증후군 치료 및 예방용 조성물
WO2019165346A1 (en) 2018-02-23 2019-08-29 Innovate Biopharmaceuticals, Inc. Compounds and methods for treating tight junction permeability
US20210069286A1 (en) * 2018-04-09 2021-03-11 9 Meters Biopharma, Inc. Compositions and methods for treating or preventing hyperglycemia, insulin resistance, and associated organ damage

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5936065A (en) * 1993-12-06 1999-08-10 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
ES2168456T3 (es) * 1995-01-16 2002-06-16 North Sydney Area Health Serv Peptidos que afectan a los linfocitos t.
US5665389A (en) * 1995-05-24 1997-09-09 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of treating diabetes
ATE408617T1 (de) * 1996-06-11 2008-10-15 Northern Sydney And Central Co T zell antigen rezeptor peptide
US5945510A (en) * 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions
US6458925B1 (en) 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
WO2001089551A1 (en) * 2000-05-19 2001-11-29 University Of Maryland, Baltimore Method of use of peptide antagonists of zonulin to prevent or delay the onset of diabetes
US7025294B2 (en) * 2003-05-20 2006-04-11 Carter Day International, Inc. Hammermill with stub shaft rotor apparatus and method
CN101420850A (zh) * 2006-02-09 2009-04-29 阿尔巴医疗公司 紧密连接效应子的制剂
WO2008043107A2 (en) * 2006-10-06 2008-04-10 Alba Therapeutics Corporation Use of tight junction antagonists to treat inflammatory bowel disease
WO2008052185A2 (en) * 2006-10-26 2008-05-02 Alba Therapeutics Corp Materials and methods for the treatment of celiac disease

Also Published As

Publication number Publication date
US20060128626A1 (en) 2006-06-15
US8183211B2 (en) 2012-05-22
WO2001089551A1 (en) 2001-11-29
EP1282432A4 (en) 2005-06-08
US20140128321A1 (en) 2014-05-08
EP1282432A1 (en) 2003-02-12
US20050065074A1 (en) 2005-03-24
CA2409771C (en) 2008-12-02
DE60139466D1 (de) 2009-09-17
CA2409771A1 (en) 2001-11-29
EP1282432B1 (en) 2009-08-05
US7531512B2 (en) 2009-05-12
US20080269136A1 (en) 2008-10-30
JP2011213742A (ja) 2011-10-27
JP2008074869A (ja) 2008-04-03
US20100087380A1 (en) 2010-04-08
JP2003534287A (ja) 2003-11-18
US20130157943A1 (en) 2013-06-20
AU2001249067A1 (en) 2001-12-03
US7026294B2 (en) 2006-04-11

Similar Documents

Publication Publication Date Title
ATE438405T1 (de) Verwendung von peptidantagonisten des zonulin zur behandlung von diabetes
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
DE60223694D1 (de) Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
DE69936335D1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
DE69918687D1 (de) 4-phenylpiperidine zur behandlung von prutitischen hauterkrankungen
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE50009504D1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DE60123238D1 (de) Zusammensetzungen zur behandlung von autoimmunkrankheiten
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
DE60135029D1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
DE60142590D1 (de) Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE255894T1 (de) Mglur5 antagonisten zur behandlung von schmerzen und angstzuständen
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
ATE312079T1 (de) Nichtnukleoside reverse transkriptase-hemmer zur behandlung von hiv-infektion
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE69711078D1 (de) Topische verwendung von kappa-opioidrezeptoragonisten zur behandlung von augenschmerz
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
ATE173620T1 (de) Verwendung eines antagonisten von tnf-alpha zur behandlung von hautrötungen neurogenen ursprungs
DE69931487D1 (de) Verwendung von apomorphin zur behandlung der vorzeitigen ejakulation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties